| Citation: |
WANG Wei, XIE Xiaoliang, YAN Didi. Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 851-855. DOI: 10.3971/j.issn.1000-8578.2020.19.1282
|
To evaluate the short-term efficacy and predictive index of anlotinib hydrochloride capsule on advanced NSCLC patients.
We retrospectively reviewed the clinical characteristics of 83 patients with non-small cell lung cancer who had received the second-line chemotherapy. Kaplan-Meier method was used to calculate the rate of PFS. Log rank method was used for statistical test of survival curve. Cox regression model was used to analyze the influence of multiple factors on progress free survival (PFS). ROC curve was used analyze the prognostic value of multiple indicators.
Among 83 patients with advanced NSCLC, there were 0 case of CR, 10 cases of PR, 56 cases of SD and 17 cases of PD. The side-effect could be controlled. The ORR and DCR were 12.0% and 79.5%, respectively. The mPFS was 4.43 months. In univariate analysis, the patients with ECOG score≥2, hypoalbuminemia, pleural effusion, elevated GGT and CYFRA21-1, decreased Pct and vascular tumor embolus had shorter PFS. Multivariable Cox regression analysis showed ECOG score, hypoalbuminemia, pleural effusion, CYFRA21-1 and vascular tumor embolus were independent prognostic factors.
For patients with non-small cell lung cancer progressing after the second-line treatment, the third-line treatment with anlotinib is safe and effective. Patients with ECOG score≥2, increased CYFRA21-1, hypoalbuminemia, pleural effusion and vascular tumor emboli have a poor prognosis. CYFRA21-1 has relatively high predictive value.
| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi: 10.3322/caac.21442
|
| [2] |
Hisakane K, Yoh K, Nakamura N, et al. Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer[J]. Medicine (Baltimore), 2017, 96(47): e8635. doi: 10.1097/MD.0000000000008635
|
| [3] |
Villano JL, Durbin EB, Normandeau C, et al. Incidence of brain metastasis at initial presentation of lung cancer[J]. Neuro Oncol, 2015, 17(1): 122-128. doi: 10.1093/neuonc/nou099
|
| [4] |
宋勇, 高健伟.精准医学时代的晚期非小细胞肺癌内科治疗进展[J].医学研究生学报, 2017, 30(11): 1121-1127. http://www.cnki.com.cn/Article/CJFDTotal-JLYB201711001.htm
Song Y, Gao JW. Medical treatment of non-small cell lung cancer: An update[J]. Yi Xue Yan Jiu Sheng Xue Bao, 2017, 30(11): 1121-1127. http://www.cnki.com.cn/Article/CJFDTotal-JLYB201711001.htm
|
| [5] |
Han BH, Li K, Zhao YZ, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱ trial (ALTER0302)[J]. Br J Cancer, 2018, 118(5): 654-661. doi: 10.1038/bjc.2017.478
|
| [6] |
La Monica S, Cretella D, Bonelli M, et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines[J]. J Exp Clin Cancer Res, 2017, 36(1): 174. doi: 10.1186/s13046-017-0653-7
|
| [7] |
Yang MM, Xu XX, Cai J, et al. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors[J]. Int J Cancer, 2016, 139(1): 171-176. http://smartsearch.nstl.gov.cn/paper_detail.html?id=409a7936c8779d4206ab867233c27488
|
| [8] |
Toffalorio F, Santarpia M, Radice D, et al. 5'-nucleotidase cN-Ⅱ emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lungbining inhibitors of ALK cancer[J]. Oncotarget, 2018, 9(23): 16437-16450. doi: 10.18632/oncotarget.24505
|
| [9] |
Shaw AT. Combining Inhibitors of ALK and ROS1 With Other Agents for the Treatment of Non-Small Cell Lung Cancer[J]. Clin Adv Hematol Oncol, 2015, 13(5): 282-284. http://smartsearch.nstl.gov.cn/paper_detail.html?id=1440797f5b8589a9ef820898a7b6b883
|
| [10] |
Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions[J]. Lancet, 2016, 388(10043): 518-529. doi: 10.1016/S0140-6736(15)01088-0
|
| [11] |
Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors[J]. Ann Transl Med, 2014, 2(12): 123. http://old.med.wanfangdata.com.cn/viewHTMLEn/PeriodicalPaper_PM25568876.aspx
|
| [12] |
Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2017, 10: 1821-1825. doi: 10.2147/OTT.S113435
|
| [13] |
Xu J, Liu X, Yang S, et al. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(3): 264-269. doi: 10.1111/ajco.12834
|
| [14] |
Yang CX, Feng W, Wu D. Apatinib for advanced non small-cell lung cancer: A retrospective case series analysis[J]. J Cancer Res Ther, 2018, 14(1): 159-162. http://www.ncbi.nlm.nih.gov/pubmed/29516980
|
| [15] |
Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases[J]. J Clin Oncol, 2015, 33(17): 1881-1888. doi: 10.1200/JCO.2014.59.0539
|
| [16] |
Horio Y, Mizuno T, Sakao Y, et al. Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases[J]. Respirol Case Rep, 2019, 7(7): e00451. doi: 10.1002/rcr2.451
|
| [17] |
Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. doi: 10.1001/jamaoncol.2018.3039
|
| [18] |
Zhang D, Zhang CF, Huang JQ, et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage Ⅲ/Ⅳ non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study[J]. Thorac Cancer, 2018, 9(12): 1754-1762. doi: 10.1111/1759-7714.12898
|
| [19] |
Girard N, Jacoulet P, Gainet M, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice[J]. J Thorac Oncol, 2009, 4(12): 1544-1549. doi: 10.1097/JTO.0b013e3181bbf223
|
| [20] |
宋娟, 刘丹, 李镭, 等.肺癌伴发胸腔积液的临床特征及生存特点[J].华西医学, 2018, 33(1): 36-40.
Song J, Liu D, Li L, et al. Clinical features and survival of lung cancer with pleural effusions[J]. Huaxi Yi Xue, 2018, 33(1): 36-40.
|
| [21] |
Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions[J]. Respirology, 2015, 20(4): 654-659. doi: 10.1111/resp.12496
|
| [22] |
洪萍, 刘爱英.四种肿瘤标志物联合检测在肺癌诊断、治疗检测及判断预后的价值[J].临床肺科杂志, 2012, 17(4): 677-679. http://www.cnki.com.cn/Article/CJFDTotal-LCFK201204049.htm
Hong P, Liu AY. Value of serum CEA, CYFRA21-1, NSE and CA125 in lung cancer diagnosis, treatment and prognosis[J]. Lin Chuang Fei Ke Za Zhi, 2012, 17(4): 677-679. http://www.cnki.com.cn/Article/CJFDTotal-LCFK201204049.htm
|
| [23] |
卢畅, 申淑景, 毛玉焕, 等. CEA、CYFRA21-1、NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性[J].肿瘤防治研究, 2017, 44(7): 485-488. doi: 10.3971/j.issn.1000-8578.2017.16.1530
Lu C, Shen SJ, Mao YH, et al. Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation[J]. Zhong Liu Fang Zhi Yan Jiu, 2017, 44(7): 485-488. doi: 10.3971/j.issn.1000-8578.2017.16.1530
|
| [24] |
张奕加, 朱雄鹏, 刘德斌, 等.血液科血液肿瘤患者低白蛋白血症的原因及临床意义[J].中华内科杂志, 2001, 40(6): 409-410.
Zhang YJ, Zhu XP, Liu DB, et al. The causes and clinical significance of hypoalbuminemia in hematologic tumor patients[J]. Zhonghua Nei Ke Za Zhi, 2001, 40(6): 409-410.
|
| [25] |
陈泓竹, 刘建明, 周芳, 等.内源性物质代谢对药物代谢处置的影响及机制研究[J].中国临床药理学与治疗学, 2019, 24(5): 580-588. http://www.cqvip.com/QK/85070X/20195/7002056226.html
Chen HZ, Liu JM, Zhou F, et al. Effect and mechanism of endogenous metabolism on drug metabolism and disposition[J]. Zhongguo Lin Chuang Yao Li Xue Yu Zhi Liao Xue, 2019, 24(5): 580-588. http://www.cqvip.com/QK/85070X/20195/7002056226.html
|
| [26] |
Chen WH, Huang YL, Chao YK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy[J]. Ann Surg Oncol, 2015, 22(1): 338-343. doi: 10.1245/s10434-014-3881-5
|
| [27] |
Mori D, Yamasaki F, Shibaki M, et al. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma[J]. Mod Pathol, 2007, 20(6): 694-700. doi: 10.1038/modpathol.3800786
|
| [1] | LU Hui, XIE Zhengyuan. Research Progress in Noninvasive Early Diagnosis of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 75-80. DOI: 10.3971/j.issn.1000-8578.2023.22.0642 |
| [2] | ZHU Xiaoli, XU Lu. Research Progress of Markers Related to Early Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 875-879. DOI: 10.3971/j.issn.1000-8578.2022.21.1483 |
| [3] | FENG Yangchun, XU Yi, HUANG Yanchun. Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012 |
| [4] | FAN Guo-yu, WU Xiao-kui, LI Chun-guo. Diagnosis Value of Tumor Markers for Malignant Pleural Effusions[J]. Cancer Research on Prevention and Treatment, 2011, 38(04): 434-436. DOI: 10.3971/j.issn.1000-8578.2011.04.018 |
| [5] | LI Wen-li, ZHAN Shu-hui, LV Mei. Re-evaluation of Multi-tumor Marker Protein Biochip Detective System in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2011.03.014 |
| [6] | YIN Cheng-hong, WEN Yan, REN Jiang-bo, DONG Zhong, LI Jia, WAN GBao-en. Combined Different Tumor Markers in Detecting 50 Primary Hepatic Carcinoma Cases[J]. Cancer Research on Prevention and Treatment, 2005, 32(08): 502-504. DOI: 10.3971/j.issn.1000-8578.3297 |
| [7] | QU Hong-yan, PANG DA, XUE Ying-wei, et al, . Diagnosis and treatment of spleen tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 316-316. DOI: 10.3971/j.issn.1000-8578.3303 |
| [8] | CAI Xiao-qing, LI Wen-guang. The diagnosis and treatment of the bladder mixed tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(02): 133-134. DOI: 10.3971/j.issn.1000-8578.941 |
| [9] | XUE Jian-ping, WANG Xian-guang, ZHU Hu, et al, . The Experimental Study of the Use of Examining SerumTumor-specific Growth Factor (TSGF) in the Preceding Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 467-468. DOI: 10.3971/j.issn.1000-8578.479 |
| [10] | LI De-ren, JI Bing-wen. The Clinical Value of Tumor Makers in the Diagnosis, Prediction Response to Chemotherapy and Prognosis in Human Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 209-211. DOI: 10.3971/j.issn.1000-8578.2156 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: